Synopsis
Use conventional IBD medicines for their correct induction or maintenance role, prevent cumulative corticosteroid harm, and apply reliable laboratory, infection and reproductive safeguards.
- Mesalazine is effective for inducing and maintaining mild to moderate ulcerative colitis when formulation and route match extent; it has little general role in active Crohn disease.
- Rectal 5-ASA is an active treatment, not an optional extra, for proctitis and left-sided disease; combined oral and topical delivery can outperform either route alone.
- Systemic and locally acting corticosteroids induce remission but do not maintain it; steroid dependence, excess or refractoriness is a treatment outcome that demands a new strategy.
- Thiopurines have a delayed onset and are maintenance or steroid-sparing medicines, not rapid induction monotherapy; assess TPMT and individual toxicity factors before use.
- Methotrexate is prescribed once weekly, with folate and strict pregnancy prevention; daily administration is a potentially fatal medication error.
- Baseline and early blood monitoring is more frequent than stable maintenance monitoring, and a downward trend can be clinically important before a numerical stop threshold is reached.
- Before immunomodulation review vaccination, active or latent infection risk, cervical screening, skin protection, malignancy history, pregnancy plans, interactions and who owns monitoring.
- If objective disease remains active despite adequate exposure, do not prolong toxicity through indefinite dose escalation; consider advanced therapy, nutrition, endoscopy or surgery.
Key red flags
Fever, sepsis physiology, severe sore throat, spontaneous bleeding or mouth ulceration on thiopurine or methotrexate needs urgent blood count and infection assessment before another dose.
A methotrexate prescription written or taken daily rather than weekly is an emergency medication-safety incident requiring immediate specialist and toxicology advice.
New dyspnoea or diffuse lung infiltrates on methotrexate needs urgent evaluation for infection and drug-related pneumonitis.
Severe epigastric pain after thiopurine initiation suggests pancreatitis and should not be managed by continuing at a lower dose without assessment.
Do not abruptly stop prolonged systemic corticosteroid during acute illness without considering adrenal suppression and providing appropriate medical review.
Investigation priorities
Identify contraindications and create a safety comparator before conventional immunomodulation.
Management branches
Mild to moderate ulcerative colitis is suitable for a mucosal first-line strategy.
- Map proctitis, left-sided or extensive disease and choose suppository, enema and oral delivery that physically reaches the inflamed segment.
- Explain formulation, daily routine and adherence, obtain baseline renal function and check for salicylate, sulfasalazine or excipient-specific risk.
- Assess response within the agreed induction period, verifying use before declaring failure and adding corticosteroid or escalation when optimised therapy is insufficient.
- Continue effective maintenance at the simplest supported schedule, with renal surveillance and rapid assessment of suspected intolerance or flare.
Objective activity needs faster control than optimised first-line or maintenance therapy provides.
- Exclude infection and abscess, select topical, ileal-release, colonic-release, oral or intravenous corticosteroid according to anatomy and severity.
- Before prescribing, define dose schedule, taper, adverse-effect prevention and the response point at which treatment will be considered inadequate.
- Start or optimise a steroid-sparing maintenance strategy during induction rather than waiting for another relapse after taper.